Avalo Therapeutics, Inc. (AVTX)

Market Cap	7.59M
Revenue (ttm)	16.96M
Net Income (ttm)	-24.77M
Shares Out	62.87M
EPS (ttm)	-2.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,969,741
Open	0.141
Previous Close	0.141
Day's Range	0.120 - 0.147
52-Week Range	0.081 - 7.000
Beta	1.26
Analysts	Hold
Price Target	1.88 (+1,457.58%)
Earnings Date	Nov 6, 2023

About AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also devel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2015
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTX

Financial Performance

In 2022, AVTX's revenue was $18.05 million, an increase of 234.40% compared to the previous year's $5.40 million. Losses were -$41.66 million, -50.63% less than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for AVTX stock is "Hold." The 12-month stock price forecast is $1.88, which is an increase of 1,457.58% from the latest price.

Price Target

$1.88

(1,457.58% upside)

Analyst Consensus: Hold